BMO Capital Markets reiterated their buy rating on shares of Glaukos Corporation (NYSE:GKOS) in a research note published on Friday morning. BMO Capital Markets currently has a $54.00 price objective on the medical instruments supplier’s stock.
A number of other equities research analysts have also issued reports on the stock. BidaskClub upgraded shares of Glaukos Corporation from a sell rating to a hold rating in a research note on Friday. Zacks Investment Research lowered shares of Glaukos Corporation from a buy rating to a hold rating in a research note on Monday, August 7th. Piper Jaffray Companies reiterated a buy rating and set a $56.00 price objective on shares of Glaukos Corporation in a research note on Thursday, August 3rd. Finally, Roth Capital dropped their price objective on shares of Glaukos Corporation from $60.00 to $54.00 and set a buy rating on the stock in a research note on Thursday, August 3rd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $52.33.
Glaukos Corporation (GKOS) traded up 0.21% during mid-day trading on Friday, reaching $37.83. The company’s stock had a trading volume of 722,691 shares. The stock’s 50 day moving average price is $38.52 and its 200 day moving average price is $42.69. The stock’s market capitalization is $1.30 billion. Glaukos Corporation has a 1-year low of $28.72 and a 1-year high of $52.49.
WARNING: “Glaukos Corporation (GKOS) Receives “Buy” Rating from BMO Capital Markets” was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.truebluetribune.com/2017/09/02/glaukos-corporation-gkos-receives-buy-rating-from-bmo-capital-markets.html.
In related news, Director Orbimed Advisors Llc sold 325,000 shares of the stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $37.93, for a total transaction of $12,327,250.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 16.40% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in GKOS. Great West Life Assurance Co. Can acquired a new stake in Glaukos Corporation during the first quarter valued at $102,000. Ameritas Investment Partners Inc. raised its stake in Glaukos Corporation by 93.1% in the second quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 1,212 shares during the period. BNP Paribas Arbitrage SA raised its stake in Glaukos Corporation by 740.6% in the second quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 3,118 shares during the period. Prudential Financial Inc. purchased a new position in Glaukos Corporation during the first quarter valued at approximately $204,000. Finally, Caxton Associates LP purchased a new position in Glaukos Corporation during the first quarter valued at approximately $272,000.
Glaukos Corporation Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corporation Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Glaukos Corporation and related companies with MarketBeat.com’s FREE daily email newsletter.